Ziprasidone: the fifth atypical antipsychotic (Q34615595)

3 August 2017

1 reference

title

Ziprasidone: the fifth atypical antipsychotic (English)

1 reference

3 August 2017

Charles F Caley

1

1 reference

3 August 2017

Chandra K Cooper

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Annals of Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

36

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

839-851

1 reference

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride

3 August 2017

cites work

1 reference

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

21 January 2018

1 reference

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

A review of central 5-HT receptors and their function

21 January 2018

1 reference

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

Pharmacological profile of neuroleptics at human monoamine transporters

21 January 2018

1 reference

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

21 January 2018

1 reference

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

21 January 2018

1 reference

Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo

21 January 2018

1 reference

Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man.

21 January 2018

1 reference

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

21 January 2018

1 reference

New onset diabetes and atypical antipsychotics

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1A053

1 reference

3 August 2017

1 reference